Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 11, 2021
Information
Tags: 
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Pneumoviridae, Glecaprevir/pibrentasvir, Glecaprevir, Hepatitis C, Pibrentasvir, Human metapneumovirus, AbbVie
Geotags: 
United States, Massachusetts
⚠generated by AI ↴
Summary
Key Points: 
  • Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).\nEnanta\xe2\x80\x99s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET\xc2\xae (U.S.) and MAVIRET\xc2\xae (ex-U.S.) (glecaprevir/pibrentasvir).
  • Please visit www.enanta.com for more information.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005247/en/\n'


Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 at 1:20 p.m. ET.

A webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the event and will be archived for approximately 90 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

Copyright: 
Copyright Business Wire 2021